EAM
FDMT icon

Eventide Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Eventide Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-422,856
Closed -$4.57M – 212
2024
Q3 		$4.57M Sell
422,856
-458,301
-52% -$7.61M 0.08% 139
2024
Q2 		$18.5M Buy
881,157
+105,043
+14% +$2.64M 0.32% 94
2024
Q1 		$24.7M Buy
+776,114
New +$19.8M 0.39% 79

Other funds holding FDMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eventide Asset Management's FDMT Position: Q4 2024 in Review

Eventide Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 422,856 shares — an estimated $4.57M sold.

Eventide Asset Management first reported a position in FDMT in Q1 2024 and held it in 3 quarters. The position peaked at $24.7M in Q1 2024. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

  • Eventide Asset Management reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Eventide Asset Management sold 422,856 4D Molecular Therapeutics shares in Q4 2024, an estimated $4.57M.
  • Eventide Asset Management first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 3 quarters.
  • Eventide Asset Management's 4D Molecular Therapeutics position peaked at $24.7M in Q1 2024.
  • 145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Eventide Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.